Table 1 Characteristics of the AML survivors (n = 80)
Survivors contacted for the quality of life study | Participating survivors (P) | Survivors who declined participation (NP) | p -value | |
|---|---|---|---|---|
P vs. NP | ||||
No of survivors | 80 | 41 | 39 | |
Sex, N (%) | 0.509 | |||
Male | 38 (47) | 18 (44) | 20 (51) | |
Female | 42 (53) | 23 (56) | 19 (49) | |
Age at diagnosis (years) | 42.0 | 43.0 | 40.0 | 0.070 |
Median (IQRb) | (34.0 − 49.0) | (37.0 − 51.0) | (32.0 − 47.0) | |
Age at time of assessment (years) | 45.5 | 49.0 | 44.0 | 0.046 |
Median (IQR) | (38.0 − 52.5) | (41.0 − 54.0) | (38.0 − 49.0) | |
Type of AML, N (%) | 0.022 | |||
De Novo AML | 62 (77) | 27 (66) | 35 (90) | |
Secondary AMLa | 15 (19) | 12 (29) | 3 (8) | |
High-risk myelodysplastic syndrome | 3 (4) | 2 (5) | 1 (3) | |
Induction therapy, N (%) | 0.509 | |||
TAD-HAM | 38 (47) | 18 (44) | 20 (51) | |
HAM-HAM | 42 (53) | 23 (56) | 19 (49) | |
Time interval since alloSCT (years) | 3.3 (2.4 − 4.8) | 3.1 (2.4 − 4.2) | 3.7 (2.5 − 5.3) | 0.191 |
Median (IQR) | ||||
Donor, N (%) | 0.062 | |||
Related | 58 (72) | 26 (63) | 32 (82) | |
Unrelated | 22 (28) | 15 (37) | 7 (18) | |
HLA c, N (%) | 0.258 | |||
Matched | 73 (91) | 39 (95) | 34 (87) | |
Mismatched | 7 (9) | 2 (5) | 5 (13) | |
GvHD d after transplantation, N (%) | 1.000 | |||
Yes | 52 (68) | 26 (67) | 26 (68) | |
No | 25 (32) | 13 (33) | 12 (32) |